C4 Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
C4 Therapeutics, Inc. (CCCC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$26.57 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-11-03
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$30.12M.
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$86.81M.
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$16.69M.
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$104.90M, a 215.05% decline from fiscal 2020.
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $91.18M, a 68.11% increase from fiscal 2019.
- C4 Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $54.24M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$26.57M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | -$18.83M 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | -$30.12M 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$104.90M 10-K · filed 2022-02-24 | |||
| 2021-09-30 | -$20.28M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $98.12M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$86.81M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $91.18M 10-K · filed 2022-02-24 | |||
| 2020-09-30 | -$27.11M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $17.10M 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | -$16.69M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $54.24M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $64.66M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |